Scinai Immunotherapeutics Ltd., an Israeli biopharmaceutical company, operates two complementary business units: research and development (R&D) focused on inflammation and immunology therapeutics, and a contract development and manufacturing organization (CDMO) through its subsidiary Scinai Biopharma Services Ltd. Its pipeline centers on NanoAbs and the PC111 monoclonal antibody program, developed in collaboration with the Max Planck Society and University Medical Center Göttingen. Recent acquisitions expanded its CDMO footprint to include small-molecule synthesis alongside biologics. Revenues nearly doubled to $1.31 million in 2025, led by CDMO growth, while operating losses narrowed modestly to $7.54 million due to ongoing R&D investment and scale-up costs. The company’s cash position was $1.66 million at year-end 2025 with a current ratio of 1.3, underscoring continued funding needs to support operations and clinical development.